Free Trial

NewAmsterdam Pharma (NAMS) Stock Forecast & Price Target

NewAmsterdam Pharma logo
$23.87 -0.60 (-2.45%)
As of 12:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NewAmsterdam Pharma - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
1
Buy
9

Based on 10 Wall Street analysts who have issued ratings for NewAmsterdam Pharma in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 1 has given a hold rating, and 9 have given a buy rating for NAMS.

Consensus Price Target

$41.55
74.05% Upside
According to the 10 analysts' twelve-month price targets for NewAmsterdam Pharma, the average price target is $41.55. The highest price target for NAMS is $52.00, while the lowest price target for NAMS is $27.00. The average price target represents a forecasted upside of 74.05% from the current price of $23.87.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for NAMS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for NewAmsterdam Pharma and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NAMS Analyst Ratings Over Time

TypeCurrent Forecast
8/28/24 to 8/28/25
1 Month Ago
7/29/24 to 7/29/25
3 Months Ago
5/30/24 to 5/30/25
1 Year Ago
8/29/23 to 8/28/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
8 Buy rating(s)
5 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$41.55$41.30$43.00$33.80
Forecasted Upside74.05% Upside81.30% Upside137.44% Upside107.23% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Buy

NAMS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NAMS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

NewAmsterdam Pharma Stock vs. The Competition

TypeNewAmsterdam PharmaMedical CompaniesS&P 500
Consensus Rating Score
2.90
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside69.78% Upside14,583.58% Upside9.99% Upside
News Sentiment Rating
Positive News

See Recent NAMS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/25/2025Wells Fargo & Company
3 of 5 stars
Yanan Zhu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$45.00+80.00%
8/7/2025Royal Bank Of Canada
3 of 5 stars
Leonid Timashev
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$38.00 ➝ $39.00+71.73%
7/17/2025The Goldman Sachs Group
3 of 5 stars
Asad Haider
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$27.00+29.06%
6/17/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Geoff Meacham
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$42.00+112.66%
6/12/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Serge Belanger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00+95.12%
6/10/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
James Condulis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$44.00+118.25%
6/4/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Seedhouse
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$42.00+124.72%
3/3/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set Target$41.00+76.15%
2/27/2025Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
George Farmer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Outperform ➝ Sector Outperform$47.00 ➝ $52.00+147.90%
1/14/2025HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Arce
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$48.00 ➝ $48.00+95.28%
9/23/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$37.00 ➝ $37.00+132.41%
5/15/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
1/18/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$30.00+79.10%
11/22/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:52 PM ET.


NAMS Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for NewAmsterdam Pharma is $41.55, with a high forecast of $52.00 and a low forecast of $27.00.

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NewAmsterdam Pharma in the last twelve months. There is currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NAMS shares.

According to analysts, NewAmsterdam Pharma's stock has a predicted upside of 74.05% based on their 12-month stock forecasts.

NewAmsterdam Pharma has been rated by research analysts at Cantor Fitzgerald, Citigroup, Needham & Company LLC, Royal Bank Of Canada, Stifel Nicolaus, The Goldman Sachs Group, and Wells Fargo & Company in the past 90 days.

Analysts like NewAmsterdam Pharma more than other "medical" companies. The consensus rating score for NewAmsterdam Pharma is 2.90 while the average consensus rating score for "medical" companies is 2.78. Learn more on how NAMS compares to other companies.


This page (NASDAQ:NAMS) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners